The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.
Police officers and construction workers who responded on September 11, 2001, to the World Trade Center disaster in New York City and worked in its aftermath had at least twice the risk of developing the precursor for multiple myeloma compared…
Ochsner Health hematologist oncologist, Dr. Andy Dalovisio is available to comment on Multiple Myeloma and other forms of blood cancer.
JMIR Publications recently published “Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study” in JMIR Formative Research which reported that the authors launched a single-arm pilot study to investigate the feasibility of patient engagement with digital life coaching (DLC) during this intensive period.
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
Researchers at Stanford University have developed “decoy receptor” molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to be published July 26 in the Journal of Experimental Medicine (JEM), were also found to be nontoxic in monkeys, suggesting they could be used to treat humans with either of these deadly diseases, which are two of the most common blood cancers around the world.
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.
Moffitt Cancer Center has joined Dana-Farber Cancer Institute to provide free screenings to eligible adults who are at a higher risk for having or developing multiple myeloma or other related conditions. This initiative is through the PROMISE Study, a national cancer screening/cohort program to help researchers understand who is at risk based on a number of factors. The goal is to detect multiple myeloma before it becomes symptomatic and to monitor those who are at increased risk in order to study and hopefully prevent the development of the disease.
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
Mayo Clinic researchers are studying a new class of immunotherapy drugs called “bispecific antibodies” that have demonstrated potent tumor-killing activity in multiple myeloma. A paper highlighting this work was published in Blood Cancer Discovery.
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
The University of Kansas Cancer Center is the first and only site in the region to offer CAR T-cell therapy to treat multiple myeloma, a type of blood cancer that affects about 30,000 people each year.
Expert from Rutgers Cancer Institute of New Jersey shares information on symptoms, treatment and more to highlight multiple myeloma awareness month.
Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
The researchers investigated the use of genomic databases and found that tumor mutation burden was significantly inflated in Black patients compared to White patients.
As a result of the study, clinicians who are using public genomic databases need to be aware of the potential for inflated tumor mutation burden values and how that may affect therapy selection and outcomes, especially for patients from underrepresented groups.
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma.
Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.
University of Colorado Cancer Center team uses liquid biopsy to predict multiple myeloma drug resistance and sensitivity.
Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study.
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
Mayo Clinic researchers will present findings at the American Society of Hematology Annual Meeting Dec. 7–10 in Orlando.
New Mayo Clinic studies to be presented include:
DNA analysis identifies elevated risk factor for myeloma in individuals of African ancestry
Study identifies more precise assessment measures for patients newly diagnosed with chronic lymphocytic leukemia
Researchers develop method to assess cancer-fighting cell therapy’s effectiveness
Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.
The National Comprehensive Cancer Network (NCCN) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation, (aka stem cell transplant or bone marrow transplant), with step-by-step information on best practices for this blood cancer treatment